Drug Response Dx concludes first round of financing with support from QIAGEN and High-Tech Gründerfonds
10-Jan-2013 -
Drug Response Dx GmbH (DRDx GmbH) concluded its first round of financing with High-Tech Gründerfonds and QIAGEN. The investment will serve to develop a biomarker test kit for rheumatoid arthritis treatment guidance with so-called TNF-alpha inhibitors. The test is secured by a patent platform ...
ELISA
High-Tech Gründerfonds Management
Qiagen
+1